Infant Bacterial Therapeutics AB (IBT-B) Fair Value & Analysis
Healthcare · SE · Market cap 877M SEK
Fair value as of: Jul 18, 2026
From 1 valuation models · updated 3 days ago
Share price +3.5% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 43.45 – kr 81.50 · fair‑value band kr 4.93 – kr 9.33 · the kr 65.20 price screens above the kr 7.47 fair value. As of Jul 18, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Infant Bacterial Therapeutics AB (IBT-B) currently trades at kr 65.20, while our model-based Fair Value estimate is kr 7.47, implying the stock looks roughly 88.5% overvalued today. We read business quality at 57/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Revenue declined 61.5% year over year. It earns a return on equity of -60.5%. The balance sheet holds a net cash position of 144M SEK. Fundamentals as of Jul 18, 2026
Our scenario range runs from kr 4.93 (bear case) to kr 9.33 (bull case); at kr 65.20, the current price sits above that range. The share trades about 23% below its 52-week high and 51% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at -89%, IBT-B screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.
About the company
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is headquartered in Stockholm, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Infant Bacterial Therapeutics AB reported revenue of kr 0 in FY2025 versus kr 0 in FY2021. Reported net income was −kr 65.2M in FY2025.
Is IBT-B fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 4,803 MXN | -38% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.04 | R$46.95 | -10% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$102.95 | A$126.79 | +23% |
| Celltrion, Inc 068270 | 183,600 KRW | 76,325 KRW | -58% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| WuXi Biologics (Cayman) Inc 2269 | HK$32.74 | HK$24.99 | -24% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Infant Bacterial Therapeutics AB (IBT-B) undervalued?
What is the fair value of IBT-B?
What is the quality score of IBT-B?
What is the net profit margin of IBT-B?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Infant Bacterial Therapeutics AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.